ArticleStem cells (Dayton, Ohio)2011
A fibrin patch-based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling.
Article in Stem cells (Dayton, Ohio), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed.
- Rejuvenating the damaged and aged heart: lessons from development.npj biomedical innovations · 2026Review
- The Current State of Extracellular Matrix Therapy for Ischemic Heart Disease.Medical sciences (Basel, Switzerland) · 2024Review
- Large animal models for cardiac remuscularization studies: A methodological review.Frontiers in cardiovascular medicine · 2023Review
- Targeting Myocardial Fibrosis-A Magic Pill in Cardiovascular Medicine?Pharmaceutics · 2022Review
- Fibrin, Bone Marrow Cells and Macrophages Interactively Modulate Cardiomyoblast Fate.Biomedicines · 2022Article
- Fibrin with Laminin-Nidogen Reduces Fibrosis and Improves Soft Palate Regeneration Following Palatal Injury.Biomolecules · 2021Article
- Stem cell therapies in cardiac diseases: Current status and future possibilities.World journal of stem cells · 2021Review
- Cardiac mechanostructure: Using mechanics and anisotropy as inspiration for developing epicardial therapies in treating myocardial infarction.Bioactive materials · 2021Review
- Review
- Review Insights In Cardiac Tissue Engineering: Cells, Scaffolds, and Pharmacological Agents.Iranian journal of pharmaceutical research : IJPR · 2021Review
- Hypoxia as a Driving Force of Pluripotent Stem Cell Reprogramming and Differentiation to Endothelial Cells.Biomolecules · 2020Review
- Molecular mechanisms of heart regeneration.Seminars in cell & developmental biology · 2020Review
- Heart regeneration with human pluripotent stem cells: Prospects and challenges.Bioactive materials · 2020Review
- A Visible Light-Cross-Linkable, Fibrin-Gelatin-Based Bioprinted Construct with Human Cardiomyocytes and Fibroblasts.ACS biomaterials science & engineering · 2019Article
- Temporal dynamics of immune response following prolonged myocardial ischemia/reperfusion with and without cyclosporine A.Acta pharmacologica Sinica · 2019Article
- Cardiac fibrosis: potential therapeutic targets.Translational research : the journal of laboratory and clinical medicine · 2019Review
- Allogeneic Mesenchymal Stem Cells and Biomaterials: The Perfect Match for Cardiac Repair?International journal of molecular sciences · 2018Review
- New Myocyte Formation in the Adult Heart: Endogenous Sources and Therapeutic Implications.Circulation research · 2018Review
- Exploiting Advanced Hydrogel Technologies to Address Key Challenges in Regenerative Medicine.Advanced healthcare materials · 2018Review
- Stem/Progenitor Cells and Their Therapeutic Application in Cardiovascular Disease.Frontiers in cell and developmental biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
It is unknown how to use human embryonic stem cell (hESC) to effectively treat hearts with postinfarction left ventricular (LV) remodeling. Using a porcine model of postinfarction LV remodeling, this study examined the functional improvement of enhanced delivery of combined transplantation of hESC-derived endothelial cells (ECs) and hESC-derived smooth muscle cells (SMCs) with a fibrin three-dimensional (3D) porous scaffold biomatrix. To facilitate tracking the transplanted cells, the hESCs were genetically modified to stably express green fluorescent protein and luciferase (GFP/Luc). Myocardial infarction (MI) was created by ligating the first diagonal coronary artery for 60 minutes followed by reperfusion. Two million each of GFP/Luc hESC-derived ECs and SMCs were seeded in the 3D porous biomatrix patch and applied to the region of ischemia/reperfusion for cell group (MI+P+C, n = 6), whereas biomatrix without cell (MI+P, n = 5), or saline only (MI, n = 5) were applied to control group hearts with same coronary artery ligation. Functional outcome (1 and 4 weeks follow-up) of stem cell transplantation was assessed by cardiac magnetic resonance imaging. The transplantation of hESC-derived vascular cells resulted in significant LV functional improvement. Significant engraftment of hESC-derived cells was confirmed by both in vivo and ex vivo bioluminescent imaging. The mechanism underlying the functional beneficial effects of cardiac progenitor transplantation is attributed to the increased neovascularization. These findings demonstrate a promising therapeutic potential of using these hESC-derived vascular cell types and the mode of patch delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.